Professional Documents
Culture Documents
Effects of Grapefruit and Seville Orange Juices On The Pharmacokinetic Properties of Colchicine in Healthy Subjects - ScienceDirect
Effects of Grapefruit and Seville Orange Juices On The Pharmacokinetic Properties of Colchicine in Healthy Subjects - ScienceDirect
Show more
Abstract
Background
The labeling for colchicine (indicated for acute gout flares or prophylaxis)
includes strict advisories regarding drug–drug and drug–food
interactions, including warnings against consuming grapefruit or
grapefruit juice during treatment. Two of the furocoumarins in
grapefruit juice and Seville orange juice can inhibit intestinal cytochrome
P450 (CYP) isozyme 3A4 and P-glycoprotein (involved in colchicine
metabolism and transport). Severe toxicities in patients consuming these
juices while taking other drugs metabolized through these pathways have
been reported.
Objective
Two Phase I studies assessed the effects of multiple daily consumptions
of Seville orange juice or grapefruit juice on the pharmacokinetic
properties of colchicine in healthy volunteers.
Methods
Healthy volunteers were enrolled in 2 open-label, Phase I studies.
Undiluted juice (240 mL) was administered twice daily for 4 days.
Pharmacokinetic data were obtained following a single 0.6-mg dose of
colchicine before the administration of juice and again following a single
0.6-mg dose of colchicine on the final day of juice administration. In each
study, blood samples for pharmacokinetics were collected before dosing
with colchicine and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose.
All subjects were monitored for adverse events (AEs) throughout the
confinement portion of the study and were queried at the outpatient
visits. AEs were coded according to corresponding MedDRA-coded
system organ classes.
Results
Forty-four subjects received either grapefruit juice (72.7% male; 90.9%
white) or Seville orange juice (62.5% female; 100% white). Although it is
considered to be a moderate concentration-dependent CYP3A4 inhibitor,
grapefruit juice did not significantly affect the pharmacokinetic
parameters of colchicine. When colchicine was administered with Seville
orange juice, a moderate inhibitor, Cmax and AUC were decreased by
∼24% and ∼20%, respectively. Seville orange juice also caused, on
average, a 1-hour delay in Tmax. Colchicine in combination with
grapefruit or Seville orange juice was well tolerated. There were no
significant treatment-related AEs reported, and the most likely AEs were
general gastrointestinal events.
Conclusions
In contrast to label warnings based on the literature, grapefruit juice did
not affect the pharmacokinetics of colchicine. Seville orange juice
paradoxically reduced absorption of colchicine and increased Tmax, but
the clinical significance of this is unknown. Contrary to the expected
effects of inhibiting the enzymes that metabolize colchicine, neither juice
increased exposure to colchicine. However, the absence of a positive
control in these studies dictates that caution should be used when
applying these results clinically. ClinicalTrials.gov identifiers:
NCT00960193 and NCT00984009.
Previous Next
Key words
colchicine; drug interaction; grapefruit juice; pharmacokinetics;
Seville orange juice
Introduction
Consumption of citrus products in the United States is common, and
grapefruit is consumed for its health benefits as a citrus fruit that is low
in calories and rich in vitamin C, potassium, and dietary fiber. The
potential for grapefruit juice to interact with medications was first
discovered in 1989.1 It was subsequently reported that healthy subjects
who took the calcium channel antagonist felodipine with grapefruit juice
had higher felodipine plasma concentrations than did those who took the
drug with water; the higher plasma felodipine concentrations resulted in
a more pronounced effect of felodipine in terms of decreased blood
pressure and other untoward effects after ingesting as little as a single
240-mL glass of grapefruit juice.2 It has since been established and well
documented in the published literature that grapefruit juice is a
mechanism-based inhibitor of intestinal, and not hepatic, cytochrome
P450 (CYP) 3A4 isozyme (intestinal first-pass metabolism).3 Grapefruit
juice can cause increases in oral bioavailability and prolongation in the
elimination half-life of a wide range of other drugs that are CYP3A4
substrates, which can result in increased systemic drug exposure (for
recent reviews, see Seden et al,4 Won et al,5 and Hanley et al6). It has also
been reported that Seville orange juice has the same potential as does
grapefruit juice for causing food–drug interactions due to the inhibition
of intestinal CYP3A4.7 Both grapefruit juice and Seville orange juice
contain furocoumarins, of which bergamottin and 6′,7′-
dihydroxybergamottin are the main constituents and are presumed to be
the primary compounds effecting CYP3A4 inhibition.7 Both grapefruit
and Seville oranges are believed to be hybrids of pomelo (pummello),8 the
juice of which also contains furocoumarins at concentrations similar to
those in grapefruit juice.9 Medications metabolized by intestinal CYP3A4
enzyme have either a low oral bioavailability or are known to be narrow
therapeutic index drugs and are more likely to have clinically significant
interactions when coadministered with grapefruit juice and/or Seville
orange juice.
Gout, once viewed as a condition of wealthy, overindulging, overweight
men, now affects >8.3 million Americans (3.9% of the adult population).10
Gout is a painful and progressive disease that, if inadequately treated,
may lead to joint destruction and deformity, with severely compromised
quality of life. In most patients experiencing a flare, recurrent flares are
likely and, if untreated, are associated with an increased frequency and
severity of flares.11 The increase in the prevalence of gout has been linked
to increased longevity (urate levels rise with age) and unhealthy dietary
and lifestyle trends.12 The prevalences of associated comorbidities,
including obesity, hypertension, metabolic syndrome, and type 2 diabetes
mellitus, have also increased. Therefore, patients with gout often have a
number of other concomitant conditions that also require medications.
Colchicine, used for >200 years to treat acute gout flares, plays a pivotal
role in both the treatment of gout flares as well as long-term prophylaxis.
The approved dosing regimen for acute gout attacks requires a single
dose of 1.2 mg to be taken immediately on the first signs of an acute flare,
followed by a 0.6-mg dose 1 hour later, and the regimen for prophylaxis is
0.6 mg once or twice daily.
Methods
The 2 separate studies—study 1 (grapefruit juice) and study 2 (Seville
orange juice)—followed similar protocols. The primary objective of each
study was to determine the effects of multiple daily consumptions of
grapefruit juice or Seville orange juice (240 mL twice daily for 4
consecutive days) on the pharmacokinetic properties of a single 0.6-mg
oral dose of colchicine administered to healthy adult subjects under
fasting conditions. The secondary objective of each study was to assess
the tolerability of a single 0.6-mg oral dose of colchicine administered
with and without multiple daily consumptions of grapefruit juice or
Seville orange juice.
The validity of each batch run during subject analysis was determined by
evaluating the accuracy of standards and QCs. A batch run was accepted if
the standards and QCs passed acceptability criteria. The accuracy and
precision of the validation of the bioanalytical method for colchicine was
accomplished by analyzing 3 standard curves prepared in human plasma
and consisting of 9 concentrations prepared in duplicate in 3 separate
batches. QCs were also prepared to assess accuracy, precision, and
stability. The standard curve concentrations ranged from 0.2000 to 40.00
ng/mL. The concentrations of the QCs were 0.2000, 0.6000, 3.200, 16.00,
and 32.00 ng/mL.
Accuracy was defined as the difference between the mean of a set of results
and the “true” value (reported as a percentage; %bias). Precision was
defined as the %CV of individual replicates from the calculated values.
The between-batch accuracy for standards was between 98.57% and
101.92%, while precision was ≤5.60%. The between-batch accuracy of QCs
was between 101.17% and 106.22%, while precision was ≤6.38%. The
between-batch accuracy for standards was between 98.57% and 101.92%,
while precision was ≤5.60%. The between-batch accuracy of QCs was
between 101.17% and 106.22%, while precision was ≤6.38%. Within-batch
accuracy and precision were assessed by analyzing 6 replicates of QCs at 5
different concentrations (0.2000, 0.6000, 3.200, 16.00, and 32.00 ng/mL).
The within-batch accuracy ranged from 96.75% to 109.17%, and precision
was ≤5.93%. This method was demonstrated to accurately and precisely
quantify all standards and QC samples.
Subjects
Subjects in each study were recruited using identical recruitment criteria.
Nonobese (body mass index, 18–32 kg/m2) adults aged 18 to 45 years of
either sex considered healthy on the basis of medical history, physical
examination, routine laboratory tests (especially for renal and hepatic
function), vital signs, and ECG were eligible for entry into the studies. All
subjects had to be nonsmokers (including use of nicotine-containing
products) for ≥6 months. Women had to be surgically sterile
(hysterectomy or bilateral oophorectomy) or had undergone bilateral
tubal ligation ≥6 months before study entry, be sexually inactive for ≥14
days before the first dose and throughout the study, have sexual activity
restricted to a partner who had undergone surgical sterilization ≥6
months prior, or undertake a reliable method of contraception (oral,
injectable, topical, or intravaginal hormone contraception for ≥3 months;
nonhormonal intrauterine device for ≥3 months and throughout the
study; or a barrier method with spermicide for ≥14 days before the first
dose and throughout the study). Exclusion criteria included known
allergy to colchicine; inability to consume, or food allergy to, grapefruit
juice or Seville orange juice (depending on the study); history or presence
of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary
tract, renal, hematologic, gastrointestinal (GI), endocrine, immunologic,
dermatologic, neurologic, or psychiatric disease; use of any drugs or
substances known to inhibit CYP enzymes and/or P-gp in the 4 weeks
before the first dose and throughout the study; positive test result for
HIV or hepatitis B or C at screening; history or evidence of alcoholism or
drug abuse in the previous 2 years; active sexually transmitted disease;
use of a special diet in the 4 weeks before the first dose; reported
difficulty in fasting or consuming standardized meals; hemoglobin <11.5
g/dL; inadequate venous access for repeated venipuncture; blood
donation of 50 to 499 mL within 4 weeks and >499 mL within 8 weeks
before the first dose; blood donation of >500 mL in 2 weeks, >1500 mL in
6 months, or >2500 mL in 1 year at completion of the study; donation of
plasma in the 4 weeks before the first dose; participation in any other
clinical trial within 4 weeks before the first dose; and pregnancy or
breastfeeding in women.
Study Design
The subjects were recruited and studied at a single US clinical study
center (Cetero Research, Fargo, North Dakota), and the study protocols
received approval from the institutional review board at PRACS Institute,
Ltd (Fargo, North Dakota). All subjects provided written informed
consent before participation in the studies, which were conducted in
accordance with the US Code of Federal Regulations and International
Conference on Harmonisation Guidelines for Good Clinical Practice and
adhered to the ethical principles of the Declaration of Helsinki.
The design of each study was identical except for the type of citrus juice
administered (grapefruit juice vs Seville orange juice) (Figure 1). These
Phase I, open-label, nonrandomized, 1-sequence, 2-period
pharmacokinetic food–drug interaction studies evaluated the effects of
the consumption of 240 mL of citrus juice (grapefruit juice or Seville
orange juice in the respective studies) twice daily for 4 consecutive days
on the single-dose pharmacokinetic properties of colchicine (0.6-mg
tablet) in a fasting state. Following a 4-week screening period (days −28 to
−2), subjects were treated with colchicine 0.6 mg given with 240 mL of
water on the morning of day 1 at 7:15 AM. After a washout period ≥14 days,
subjects received citrus juice (grapefruit juice or Seville orange juice) 240
mL twice daily on days 15 to 18 at 7:15 AM and 7:15 PM; when not confined,
the subjects visited the clinic on a nonconfined basis to receive
administration of citrus juices. Study subjects then received a single dose
of colchicine 0.6 mg in combination with 240 mL of citrus juice on the
morning of day 18. Subjects were admitted to the clinical facility for ∼36
hours (∼12 hours before dosing and through ∼24 hours after dosing) for
each period of colchicine dosing alone and in combination with citrus
juices (days −1 to 2 and days 17 to 19, respectively). Subjects were dosed in
pairs at 1-minute intervals as a single cohort and in the same sequence
during each test period. Colchicine doses were administered after
completing an overnight fast (10 hours). Compliance was confirmed by
oral cavity and hand inspection. No food was permitted until ≥4 hours
after dosing. During clinic confinement on days 1 and 18, standardized
meals and beverages (free from grapefruit, xanthine- and caffeine-
containing products) were provided at 4:25 AM and 10:25 AM, and a
standardized snack was provide at 2:25 PM, after colchicine
administrations. Meals and snacks were identical during each study
period. Water was allowed ad libitum starting 2 hours after colchicine
administration. Grapefruit juice was administered as a commercial brand
Thirster 100% Grapefruit Juice (Rituals Coffee Co, Columbia, Maryland;
lot no.: L 504; expiration date, February 6, 2009), and Seville orange juice
was provided as hand-squeezed juice from fresh Seville oranges that was
sweetened with 1 tablespoon of aspartame (Equal, The Merisant
Company, Chicago, Illinois) to ensure patient compliance. Seville orange
juice was obtained by soaking Seville oranges in tepid water for 20
minutes, at which time the rind was removed using a peeler. After
removal of the rind, the oranges were then put into a juicer, where the
pulp was separated from the rest of the juice. Once juicing was complete,
all Seville orange juice was batch frozen to −20°C. The necessary amount
of orange juice was removed from the freezer and thawed to room
temperature 24 hours prior to administration. Grapefruit juice was
refrigerated at 2.8°C to 4.5°C (37°F to 40°F) until dispensed. Neither juice
was analyzed for inhibitory components.
Download : Download high-res image (189KB) Download : Download full-size image
Subjects were free to withdraw from the study at any time for any reason.
Furthermore, subjects could be withdrawn by the investigator in the case
of unnecessary risk, AEs, or noncompliance.
Pharmacokinetic Measurements
Methods of pharmacokinetic measurement were identical in each study.
Blood (6-mL aliquots) was taken by direct venipuncture before dosing
(time 0) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on days
1 and 18 (during confinement) and at 36, 48, 72, and 96 hours postdose
(returning to the clinic on a nonconfined basis). All blood samples (192
mL) were collected into K2-EDTA tubes, kept on ice, and then centrifuged
at ∼2500g at 4°C for 15 minutes. Plasma samples were stored at −20°C or
colder and transferred to the bioanalytical laboratory (Cetero Research),
where they were assayed, by personnel masked as to the study details or
sequence, for colchicine using a validated method of LC-MS/MS.
Statistical Analysis
Statistical analysis was identical in each study. No formal sample size
determination was performed. However, it was estimated that 24 subjects
would be adequate based on sample sizes used in other published drug–
food interaction studies with citrus juices.23 It has also been reported to
be sufficient for detecting significant interactions with colchicine in
drug–drug interaction studies undertaken by the sponsor.23
Results
In study 1 (grapefruit juice), all subjects received the first dose of study
medication on September 13, 2008, and the last pharmacokinetic blood
sample was collected on October 4, 2008. In study 2 (Seville orange juice),
all subjects received the first dose of study medication on February 19,
2009, and the last pharmacokinetic blood sample was collected on March
9, 2009.
Black 2 (9.1) 0
CL/F = apparent total body clearance; kel = apparent first-order terminal elimination
rate constant; Varea/F = apparent total volume of distribution.
Median (range).
†
An underestimation because the majority of plasma concentrations were not
quantifiable by 24 hours postdose.
Property Colchicine With Seville Orange Colchicine Without Seville Orange Juice
Juice (Test) (Reference)
Property Mean (SD)
Colchicine %CV
With Seville Orange Mean
Colchicine (SD) Seville Orange
Without %CVJuice
Juice (Test) (Reference)
CL/F = apparent total body clearance; kel = apparent first-order terminal elimination
rate constant; Varea/F = apparent total volume of distribution.
Median (range).
Tolerability
All subjects were monitored for AEs throughout the confinement portion
of the study and queried during the nonconfinement visits. Blood
pressure (sitting for ≥5 minutes) and pulse were measured prior to dosing
(time 0) and at 1, 2, and 3 hours postdose on days 1 and 18, as well as at
screening, each check-in, and study exit (day 19 or early termination). All
subjects underwent clinical laboratory testing, including hematology,
biochemistry, urinalysis, and in women, pregnancy testing at screening,
baseline, period 2 check-in (day 17), and prior to discharge from the study
(urinalysis was not done at discharge). A full physical examination was
performed at screening, with targeted physical examinations conducted
at baseline, day 18, and study discharge if needed in response to AEs or
changes in medical history.
Study 1 Study 2
AE by preferred
term
Dyspepsia 0 0 1 (4.2) 0
Pyrexia 0 0 1 (4.2) 0
Pain 0 0 1 (4.2) 0
Discussion
Consumption of grapefruit juice (240 mL twice daily for 4 consecutive
days) had no statistically or clinically significant effects on the
pharmacokinetic properties of colchicine following the oral
administration of a single 0.6-mg dose in healthy subjects in a fasted state
except for a marginal but statistically significant increase in median Tmax,
from 1.0 to 1.5 hours (P = 0.0156). Paradoxically, consumption of Seville
orange juice (240 mL twice daily for 4 consecutive days) decreased
colchicine Cmax and overall total colchicine exposure (AUC values) by
∼25% and ∼20%, respectively, on the basis of ln-transformed geometric
mean values. Median colchicine Tmax was also significantly increased,
from 1.0 to 2.0 hours (P < 0.0001), delayed by ∼1 hour during Seville
orange juice consumption. The clinical significance of this finding is
unknown. The findings of these 2 studies were unexpected, because
previous studies and case reports in the literature indicated that both
citrus juices would be expected to increase systemic colchicine exposures.
Review of the literature reveals few data regarding the potential for
interaction between colchicine and grapefruit juice. A single case report
of near-fatal acute colchicine toxicity with concurrent consumption of
grapefruit juice was reported in an 8-year-old girl with familial
Mediterranean fever.38 This patient had been prescribed colchicine 2
mg/d for 10 months and, during the 2 months preceding hospital
admission, was ingesting 1000 mL/d of grapefruit juice. She developed
fever, recurrent vomiting, severe abdominal pain, and a sore throat. She
was hospitalized 2 days later for an acute attack of familial Mediterranean
fever. By day 2, the patient developed circulatory shock and pancytopenia,
requiring intubation, fluid support, inotropic agents, fresh frozen
plasma, vitamin K, and granulocyte colony-stimulating factor. The
patient's clinical condition improved and stabilized during the following
days. Delayed pathologies present in the second week of hospitalization
included practically total alopecia, atonic falls, weakness, and an elevated
white blood cell count, with no signs of infection. These symptoms
resolved by the patient's discharge from the hospital on day 24. Based on
a thorough search of the published literature, there have been no other
reports concerning the potential interaction between grapefruit juice and
colchicine to the authors' knowledge.
Conclusions
In consideration of the fact that a positive control was not used in either
study, based on mechanism of action as a moderate CYP3A4 inhibitor,
grapefruit juice unexpectedly did not affect the pharmacokinetic
properties of colchicine. Paradoxically, Seville orange juice reduced Cmax
and AUC and increased Tmax. Colchicine administered in combination
with either juice was well tolerated.
Conflicts of Interest
The data and information presented in this manuscript was developed in
accordance with the PRISM (PRogram to Improve the Safety of
Medication) initiative (URL Pharma, Inc, Philadelphia, Pennsylvania). The
provider of study funding did not have influence on study design; data
collection, analysis, or interpretation; preparation or review of the report;
or the decision to submit for publication.
Acknowledgments
Medical editorial assistance was provided by Peter Todd, PhD, and James
A. Shiffer, RPh, Write On Time Medical Communications, LLC, and was
funded by Mutual Pharmaceutical Company, Inc, a wholly owned
subsidiary of URL Pharma, Inc. The authors also acknowledge Thomas
Lauterio, PhD, and Deborah DeMaria, MS (Mutual Pharmaceutical
Company, Inc.), for their review and critical revisions for important
intellectual content. All authors contributed equally to the literature
search, data interpretation, figure creation, and writing of the
manuscript.
Recommended articles
References
1 D.G. Bailey, J.D. Spence, B. Edgar, et al.
Ethanol enhances the hemodynamic effects of felodipine
Clin Invest Med, 12 (1989), pp. 357-362
View Record in Scopus Google Scholar
8 R.W. Scora
On the history and origin of citrus
Bull Torry Bot Club, 102 (1975), pp. 369-375
CrossRef View Record in Scopus Google Scholar
18 R.A. Terkeltaub
Colchicine update: 2008
Semin Arthritis Rheum, 38 (2009), pp. 411-419
Article Download PDF View Record in Scopus Google Scholar
27 D.G. Bailey
Fruit juice inhibition of uptake transport: a new type of food–drug
interaction
Br J Clin Pharmacol, 70 (2010), pp. 645-655
CrossRef View Record in Scopus Google Scholar
Cited by (16)
Show abstract
Show abstract
Show abstract
Colchicine effect on P-glycoprotein expression and activity: In
silico and in vitro studies
2014, Chemico-Biological Interactions
Show abstract
Data from this study were presented in part in abstract and poster format at the Annual
Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 2–5, 2011;
Dallas, Texas.